Bulk Brucella abortus strain A19 live antigen is introduced into finished veterinary vaccine manufacture at the concentrated harvest stage, where the downstream target is a lyophilized injectable for subcutaneous calfhood administration to cattle and buffalo calves aged 4–8 months. In this application the antigen is standardized to a pre-fill viable count of 5 × 10^10 CFU per 2.0 mL dose, equivalent to 2.5 × 10^10 CFU/mL after reconstitution. The formulation addition ratio begins with a 1:1 v/v mixing of bulk antigen concentrate and a 2× stabilizer solution, producing final stabilizer concentrations of 5% w/v sucrose and 1% w/v gelatin, with 0.5% w/v sodium glutamate where low residual moisture is required. Production sequence consists of seed revival from a master cell bank, expansion in Brucella broth base at 37 °C and pH 6.8 with dissolved oxygen maintained above 30% saturation, harvest at late-log phase, concentration by disc-stack centrifugation at 15,000 × g, blending with the stabilizer matrix, and filling into Type I borosilicate vials under aseptic conditions. Lyophilization is performed with a shelf temperature setpoint of −35 °C during primary drying and chamber pressure of 80 mTorr, followed by secondary drying to a residual moisture specification of ≤3.0% w/w. Terminal finished product types are 10-dose and 20-dose lyophilized pellet vials stored at 2–8 °C. Compliance for this presentation is anchored to USDA 9 CFR 113.65 as the strain 19 equivalence monograph, OIE Manual Chapter 3.1.4 for Brucella vaccine strain A19, and Ph. Eur. 0793 for live Brucella vaccine for veterinary use. Because live Brucella cells cannot pass a sterilizing-grade filter, terminal sterilization is absent; all downstream handling from harvest through capping occurs inside BSL-3 containment with aseptic processing validated under ISO 13408-1:2008. Oral solid dosage forms such as tablets, capsules, granules, and premix are not established commercial presentations for this live antigen because gastric acid exposure and intestinal enzyme activity reduce viable count below the immunizing threshold.

Batch-to-batch viability drift in this route is observed when the harvested cell paste hold time exceeds 2 h at 20 °C before stabilizer blending; live Brucella abortus strain A19 suspensions lose metabolic activity faster than freeze-dried cake, so the manufacturing line is scheduled to complete harvest-to-fill within 4 h at 2–8 °C. The lyophilizer must be qualified for shelf temperature uniformity of ±1 °C across the shelf stack, and the ice nucleation front during freezing is controlled by an annealing step at −5 °C for 2–3 h to reduce cake collapse at the vial edge. Vial breakage on the line is mitigated by using Type I borosilicate glass with a fill depth not exceeding 1.5 cm; excessive fill depth extends primary drying time and produces heterogeneous residual moisture. The finished lyophilized pellet is capped under nitrogen to reduce oxidative damage to the bacterial membrane, and capping torque is validated in the range 8–14 in-lb to maintain container closure integrity. Stability after reconstitution is limited at room temperature; once the diluent is added, the suspension should be administered within 2 h to avoid loss of dose viability.

Liquid injectable presentations of Brucella abortus strain A19 are manufactured for small ruminant labels where national registrations allow subcutaneous administration of a reduced dose. The bulk antigen is diluted to a final viable count of 1.0 × 10^10 CFU per 1.0 mL dose, though published data for this specific configuration in sheep and goats is limited and must be confirmed against the importing country’s pharmacopoeia. Formulation addition uses sterile phosphate-buffered saline pH 7.2 containing 0.85% w/v NaCl, added at a 1:1 to 1:9 volumetric ratio depending on harvest titre. The production process is shorter than the lyophilized route: harvested concentrate is diluted in a closed stainless-steel mixing vessel, held at 2–8 °C for no more than 2 h, and filled into 50 mL or 100 mL multi-dose vials through a peristaltic pump fitted with single-use silicone tubing. Sedimentation is controlled by continuous magnetic stirring at 120 rpm during filling. Terminal finished product types are 50 mL and 100 mL liquid suspensions for subcutaneous injection. Compliance is anchored to OIE Manual Chapter 3.1.4 and to national pharmacopoeia monographs for A19; sterility testing follows Ph. Eur. 2.6.1, and stability evaluation follows VICH GL45. The absence of lyoprotectant and the presence of free water create an operational boundary: liquid suspension must not be frozen, because freeze-thaw cycles reduce viable count through intracellular ice crystallization, and exposure above 8 °C for more than 6 h during distribution erodes dose uniformity.

The lyophilized A19 cake is co-packed with a sterile diluent for reconstitution at the point of vaccination. The diluent is prepared from water for injection with 0.85% w/v NaCl and phosphate buffer to pH 7.2, filled into Type I glass vials at 2.0 mL per single dose or 20.0 mL per 10-dose vial, and terminally sterilized by autoclaving at 121 °C for 15 min. The addition ratio is fixed by the finished vaccine label, not by bulk antigen titre, since the diluent carries no antigen. Compliance for the diluent includes Ph. Eur. 5.1.1 for sterile preparation and Ph. Eur. 2.6.14 for bacterial endotoxin with a limit of ≤0.5 EU/mL. Terminal product types are 2 mL and 20 mL diluent vials co-packed with lyophilized vaccine vials.

Aseptic filling is the controlling unit operation for strain A19 live injectable powders and liquid suspensions because the viable bacterial cells are retained by sterilizing-grade filters and are destroyed by heat, radiation, and ethylene oxide. The filling line therefore operates without a terminal microbial kill step, and process capability is demonstrated by media fills rather than by finished-product terminal sterilization. Fill volume is set at 2.2 mL per vial for a nominal 2.0 mL dose, a 10% overfill allowance to compensate for needle retention and syringe dead volume. The addition ratio is a function of the post-harvest titre: bulk antigen concentrate is adjusted to 2.5 × 10^10 CFU/mL prior to filling for cattle presentations, or 1.0 × 10^10 CFU/mL for reduced-dose small ruminant presentations, by dilution with sterile stabilizer or phosphate buffer. Filling is performed with a peristaltic pump and single-use silicone tubing inside a BSL-3 isolator, with continuous mixing at 100–150 rpm to prevent sedimentation, and with vial capping performed under unidirectional airflow. Terminal finished product types are liquid suspensions and pre-lyophilization filled vials in 10-dose, 20-dose, and 100 mL configurations. Compliance for aseptic processing is anchored to ISO 13408-1:2008, USDA 9 CFR 101–118 for veterinary biological product filling and labeling, and Ph. Eur. 5.1.1; environmental monitoring of the filling zone follows ISO 14644-1 Class A limits with ≥0.5 µm particle counts. Aseptic process validation requires three consecutive media fill runs with no more than 0.1% contaminated units at 95% confidence, according to current industry acceptance rules.

Formulation of bulk freeze-dried A19 powder for further manufacture requires a stabilizer system that balances glass transition, collapse resistance, and viable cell recovery. A common matrix is prepared as a 2× concentrate containing 10% w/v sucrose and 2% w/v gelatin, which is mixed 1:1 with bulk antigen to final concentrations of 5% w/v sucrose and 1% w/v gelatin; the residual moisture specification after lyophilization is ≤3.0% w/w. Thermal characterization of the formulated suspension is performed by differential scanning calorimetry to identify the glass transition temperature of the maximally freeze-concentrated solution, and freeze-drying microscopy is used to confirm collapse temperature before cycle scale-up. The production process includes an annealing step at −5 °C for 3 h to promote ice crystal uniformity, followed by primary drying at −30 °C shelf setpoint and 100 mTorr chamber pressure, and secondary drying at 25 °C until residual moisture reaches specification. Terminal product types are bulk lyophilized powder packed in single-use containers for further aseptic re-formulation or direct filling into finished vial presentations. Compliance for the freeze-dried powder includes USDA 9 CFR 113.65 viable count stability, OIE Manual Chapter 3.1.4, and Ph. Eur. 0793 for live Brucella vaccine. A known operational boundary is the incompatibility of the stabilizer with phosphate-buffered saline at concentrations above 10 mM phosphate during lyophilization, which can cause pH shifts and accelerated viability loss; published data for this specific configuration is limited, and cycle parameters are confirmed on a per-matrix basis.